Moving past a patient death, Poseida offers an early snapshot of proof of efficacy for a next-gen solid tumor CAR-T
Ten months after the FDA took the shackles off Poseida’s study for a CAR-T directed against castrate-resistant prostate cancer, the executive team is now rolling out an early snapshot of the proof-of-concept data it’s looking for in a small, early-stage study.
Tested in 9 heavily pre-treated patients — with an average of 6 prior therapies — investigators tracked a significant, 50%-plus drop in PSA levels in 3 of those patients and what they called a “concordant” imaging result for tumor effect. One patient had a complete response — the ideal result for any cancer study.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.